Slovačka - slovački - ŠÚKL (Štátny ústav pre kontrolu liečiv)

recordati industria chimica e farmaceutica s.p.a., taliansko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovačka - slovački - ŠÚKL (Štátny ústav pre kontrolu liečiv)

recordati industria chimica e farmaceutica s.p.a., taliansko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovačka - slovački - ŠÚKL (Štátny ústav pre kontrolu liečiv)

recordati industria chimica e farmaceutica s.p.a., taliansko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Europska Unija - slovački - EMA (European Medicines Agency)

virbac s.a. - osaterón acetát - urologika - psy - liečba benígnej hypertrofie prostaty (bph) u mužských psov.

Slovačka - slovački - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Europska Unija - slovački - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatické nádory - endokrinná terapia - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Europska Unija - slovački - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatické nádory - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Europska Unija - slovački - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatické nádory - endokrinná terapia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Europska Unija - slovački - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterón acetátu - prostatické nádory - endokrinná terapia - zytiga je uvedená s prednizónom alebo prednisolone na:liečbu metastatickým kastrácia odolný proti rakovine prostaty u dospelých mužov, ktorí sú bez príznakov alebo mierne symptomatických po poruche androgén deprivácie terapia, pri ktorej chemoterapia nie je zatiaľ klinicky indicatedthe liečbu metastatickým kastrácia odolný proti rakovine prostaty u dospelých mužov, ktorých choroba pokročila na alebo po docetaxel založené chemoterapia režim.

Europska Unija - slovački - EMA (European Medicines Agency)

krka, d.d., novo mesto - abiraterón acetátu - prostatické nádory - endokrinná terapia - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.